Summit Therapeutics Share Discussion Threads

[algernon2] 02/6/2020 23:10

"Due to the uncertainties surrounding COVID-19, Summit Therapeutics is withdrawing public commentary on the timing of completion of the Phase 3 Ri-CoDIFy clinical trials. The Company will be updating stakeholders quarterly as to enrollment status."

Thanks Waterloo.

[waterloo01] 02/6/2020 21:03

Withdraws guidance on when trials will be enrolled.

[chrisatrdg] 21/5/2020 19:59

Summit on the move again on the NASDAQ possible assisted by the following article:

[chrisatrdg] 12/5/2020 11:38

SEC Schedules on NASDAQ website not yet on Summit website for P/E 31ST Dec 2019:

[kirk 6] 11/5/2020 18:11

Thanks Chris with the spike to $5.5 the other day this has probably been the best stock for me over the past year after bringing UK average down to 21.7

[chrisatrdg] 07/5/2020 17:42

Well done kirk6 I wish I had held back selling earlier myself but thats life now have 50% of AIM number now holding 5,200 dwarfed by your holdings but I am now holding to next year & might Buy back in if shares I hold in INFA finally rocket back up.Regards.

[kirk 6] 07/5/2020 17:19

Thanks Chris interesting I sold 20000 at 5 the other spike so might buy them back now. Still hold 180k shares at a very nice profit but holding core till $8-$10

[chrisatrdg] 07/5/2020 17:13

Positive report yesterday seems now being reflected in Summits resurge on the NASDAQ today:

Summit Therapeutics PLC (SMMT) Gains As Market Dips: What You Should Know

May 06, 2020, 05:45:16 PM EDT By Zacks.com

'In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.11, marking a +0.33% move from the previous day. This change outpaced the S&P 500's 0.7% loss on the day. At the same time, the Dow lost 0.92%, and the tech-heavy Nasdaq gained 0.51%.

Investors will be hoping for strength from SMMT as it approaches its nex t earnings release. On that day, SMMT is projected to report earnings of -$0.08 per share, which would represent year-over-year growth of 60%. Our most recent consensus estimate is calling for quarterly revenue of $2.84 million, up 787.5% from the year-ago period.

Any recent changes to analyst estimates for SMMT should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 26.26% higher. SMMT is currently a Zacks Rank #1 (Strong Buy).

The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 13, putting it in the top 6% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow SMMT in the coming trading sessions, be sure to utilize Zacks.com.'

[waterloo01] 06/5/2020 18:35

They have taken so long it seems that poop treatment has caught up. Full results later in year. Can't bring myself to sell the last few, but if I had anything more than a small stake, I'd be selling on this. The main question remaining is will RDZ show superiority. It needs to otherwise it's unlikely to get far.

[chrisatrdg] 02/5/2020 11:52

I have just looked at yesterdays close on the NASDAQ & clearly the new year end accounts of 31st December & the message about the C-Diff results has clearly had an effect.

We are clearly better today than the closing on AIM & for me I am going to risk all & wait to next year although if it goes to $5 again I might be tempted.

Regards to all & stay safe.

[chrisatrdg] 30/4/2020 20:28

Hi waterloo01 - I will not give a figure but with Summits overheads now only slightly reduced those in the trials have cost a more than proportionate amount & has been an inefficient way of working especially as Summit should be about controlling the cash burn.

I have wondered why they lost the lead scientific officer who I thought was a find.

The board has been trimmed down as far as UK involvement is concerned but good to see someone from Discuva on the board.

PS: Look at the link below & spot who the CEO is & you will see what he has achieved in the same time that Summit have owned Discuva a company that he once owned & started up.

[waterloo01] 30/4/2020 18:35

Chris, not quite gone but almost. To have spent this much time and money since the start of the phase 3 and to get to those recruitment numbers.....no wonder some were pushed out. Incompetence comes to mind. 'm sure Duggan will add some much needed energy, as and when they can reopen, but as clarky says, it will mean even more money and even more time.

Will look for another anti-biotic play as I still think the sector will, at some point, turn round and that could well be sparked by COVID lack of preparedness.

Edit: Chris your an accountant. I wonder what's it's cost them to date in the phase 3 per patient recruited?

[chrisatrdg] 30/4/2020 17:37

Thank you waterloo01 So it looks like after all these years you are now 'off' but maybe Buy back in when things turn around - good luck & stay safe.

Clarkey26 - My reason for selling my 50% prematurely was because of the fears that the C-Diff trials would be adversely effected by this virus.I have now decided to stick with my remaining 50% but agree with your comments.

Regards to all & stay safe.

[clarkey26] 30/4/2020 15:24

They need just under 1400 people to take part in the trial. We knew there was a gap between current funding up to Jan 2021 and trial results being expected second half 2021 but that gap must now be bigger and require more funding now. The take up of trial places does seem low preCovid even accepting sites need to open and ramp up etc.

[waterloo01] 30/4/2020 14:39

Sold 50% of remaining holding. Trial, as expected on hold but recruitment to date is woeful. As for the numbers, the mix use of £ and $ is very confusing. Maybe it makes sense to Thetons.

[chrisatrdg] 30/4/2020 12:39

Final results RNS:



Good to see final results out today next results will be Quarter to 31st March 2020 & will be interesting to see an update on recruitment for the C-Diff phase three trials.

Will be interesting to see reaction on the NASDAQ today but for me with my remaining 50%
of the original number of ADD's transferred onto the NASDAQ standing now at 5,200 ADD's it is a matter of waiting.

[algernon2] 14/4/2020 20:27

Yes very nice price rise today.
Will miss Glyn's steady hand at the helm. Always a good speaker and a thoroughly decent man.

[chrisatrdg] 14/4/2020 19:45

Well done all I however have sold 50% in the last week £11k (5,150 ADD's) 50% loss but my remaining 5,150 are currently worth £20k plus & I am holding until 2nd half 2021.Never could get it right.Confession over.

[hernando2] 14/4/2020 19:44

Feels like a pump and dump....funding coming.

Who cares though

[1gw] 14/4/2020 17:07

Spectacular. Well done to those who out-stayed me.

[waterloo01] 14/4/2020 16:30

Well done. Don't crash the price when you start selling!

[kirk 6] 14/4/2020 16:09

Told everyone on here this would fly on the Nasdaq Medium term $10

[kirk 6] 14/4/2020 16:09

Having an orgasm

[hernando2] 14/4/2020 15:43

Yanks like yanks in the driving seat, the is the best of both worlds up a decent bit on the news as opposed to selling the news after yesterdays spike up

[waterloo01] 14/4/2020 14:59

End of an era.